Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men

Trial Profile

Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs BAY 1902607 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Bayer
  • Most Recent Events

    • 02 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2018 Planned End Date changed from 7 Jun 2018 to 19 Jul 2018.
    • 09 May 2018 Planned End Date changed from 15 Jun 2018 to 7 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top